NEOGEN CORP
10-Q, EX-27, 2000-10-12
IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
Previous: NEOGEN CORP, 10-Q, EX-10.1, 2000-10-12
Next: SILICON VALLEY GROUP INC, SC 13G/A, 2000-10-12



<TABLE> <S> <C>

<PAGE>

<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM CONSOLIDATED
BALANCE SHEET AND CONSOLIDATED STATEMENTS OF INCOME AND IS QUALIFIED IN ITS
ENTIRETY BY REFERENCE TO SUCH FINANCIAL STATEMENTS.
</LEGEND>

<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                          MAY-31-2001
<PERIOD-START>                             JUN-01-2000
<PERIOD-END>                               AUG-31-2000
<CASH>                                       1,169,000
<SECURITIES>                                 5,347,000
<RECEIVABLES>                                6,359,000
<ALLOWANCES>                                   471,000
<INVENTORY>                                  5,779,000
<CURRENT-ASSETS>                            19,020,000
<PP&E>                                       7,005,000
<DEPRECIATION>                               4,404,000
<TOTAL-ASSETS>                              29,337,000
<CURRENT-LIABILITIES>                        3,030,000
<BONDS>                                              0
                                0
                                          0
<COMMON>                                       910,000
<OTHER-SE>                                  25,022,000
<TOTAL-LIABILITY-AND-EQUITY>                29,337,000
<SALES>                                      8,124,000
<TOTAL-REVENUES>                             8,304,000
<CGS>                                        4,128,000
<TOTAL-COSTS>                                7,322,000
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                              10,000
<INCOME-PRETAX>                                972,000
<INCOME-TAX>                                   300,000
<INCOME-CONTINUING>                            672,000
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                   672,000
<EPS-BASIC>                                       0.12
<EPS-DILUTED>                                     0.12


</TABLE>


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission